Related Experiment Videos
[Etoposide 21 therapy for malignant lymphoma]
1Medical Center for Cancer and Cardiovascular Disease Osaka.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|December 1, 1996
Summary
Oral etoposide therapy offers a palliative option for malignant lymphoma patients unsuitable for intensive treatment. This regimen demonstrated a 52.5% overall response rate with manageable side effects, improving quality of life.
Area of Science:
- Oncology
- Pharmacology
Context:
- Malignant lymphoma treatment often involves intensive therapies.
- Certain patient populations are not candidates for intensive treatment regimens.
Purpose:
- To evaluate the efficacy and tolerability of oral etoposide in patients with malignant lymphoma not indicated for intensive treatment.
Summary:
- A study involving 83 patients with malignant lymphoma assessed oral etoposide (50 mg daily for 21 days, with dose escalation to 75 mg allowed).
- The overall response rate was 52.5%, with higher responses in previously untreated patients (81.8%) and those receiving 75 mg (85.7%).
- Moderate side effects like loss of appetite, nausea, and leukocytopenia were observed but were manageable.
Impact:
- Oral etoposide provides a viable palliative therapy option for select malignant lymphoma patients.
- This approach allows patients to receive treatment at home, potentially maintaining a higher quality of life.